US Stock MarketDetailed Quotes
TLSI TriSalus Life Sciences
- 4.900
- -0.260-5.04%
Close Jan 13 16:00 ET
149.42MMarket Cap-2.55P/E (TTM)
5.160High4.830Low26.36KVolume4.830Open5.160Pre Close130.93KTurnover0.13%Turnover RatioLossP/E (Static)30.49MShares10.42052wk High-7.31P/B98.03MFloat Cap3.50052wk Low--Dividend TTM20.01MShs Float16.240Historical High--Div YieldTTM6.40%Amplitude3.320Historical Low4.967Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
TriSalus Life Sciences Stock Forum
Businesswire· 08:008mins
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative del...
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
January 09, 2025 08:00 AM Eastern Standard Time
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our inn...
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
TriSalus Life Sciences (Nasdaq: TLSI) announced the publication of research in the Journal of Vascular and Interventional Radiology demonstrating improved delivery of glass microspheres to liver tumors using their Pressure Enabled Drug Del...
No comment yet